Recent progress in the pathogenesis and management of essential thrombocythemia

Leukemia Research

Volumn 25, Issue 5, 2001, Pages 369-377

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic myeloproliferative disease; Cytoreductive therapy; Essential thrombocythemia; Hematopoiesis; Thrombopoietin; Thrombosis

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CYTOKINE; HYDROXYUREA; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PHOSPHORUS 32; PIPOBROMAN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADVERSE DRUG REACTION; BLEEDING; BONE MARROW SUPPRESSION; FLU LIKE SYNDROME; GENE MUTATION; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; INCIDENCE; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS; X CHROMOSOME INACTIVATION;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 0035071899     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00131-4     Document Type: Review

References (110)

1. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview
2. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group
3. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment
4. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995
5. Age and sex distributions of hematological malignancies in the UK
6. Essential thrombocythemia in children
7. Clinical course of essential thrombocythemia in 147 cases
8. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
9. Regulation of X-chromosome inactivation in development in mice and humans
10. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors
11. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors
12. A novel clonality assay based on transcriptional analysis of the active X chromosome
13. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction
14. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
15. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia
16. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets
17. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
18. Essential thrombocythemia in two sisters originating from different stem cell levels
19. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes
20. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age
21. X chromosome inactivation patterns in normal females
22. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age
23. An X chromosome gene regulates hematopoietic stem cell kinetics
24. Clonality analysis of granulocytes and T lymphocytes in healthy females by the PCR-based HUMARA method
25. Monoclonal gammopathies of undetermined significance
26. Thrombopoietin: the primary regulator of platelet production
27. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes
28. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets
29. Human platelets as a model for the binding and degradation of thrombopoietin
30. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics
31. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis
32. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels
33. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia
34. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates
35. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia
36. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes
37. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
38. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis
39. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera
40. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value
41. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera
42. Serial serum thrombopoietin levels in a pregnant woman with essential thrombocythaemia
43. Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia
44. High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin
45. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene
46. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
47. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene
48. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia
49. Study of the thrombopoietin receptor in essential thrombocythemia
50. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-β receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-β itself with high specificity
51. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells
52. Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders
53. Characteristics of megakaryocyte colony formation in normal individuals and in primary thrombocythemia: studies using an optimal cloning system
54. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications
55. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia
56. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis
57. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF
58. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L
59. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders
60. A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl
61. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3
62. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development of factor (PEG-rHu MGDF) in essential thrombocythemia (abstract)
63. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
64. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients
65. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
66. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients
67. Sex and age as prognostic factors in essential thrombocythemia
68. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors
69. Essential thrombocythemias. Clinical evolutionary and biological data
70. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases
71. Acquired von Willebrand's disease in the myeloproliferative syndrome
72. Patients with essential thrombocythemia and clonal hemopoiesis detected by X-inactivation pattern are at high risk for thrombotic complication (abstract)
73. No treatment for low-risk thrombocythaemia: results from a prospective study
74. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia
75. The use of aspirin in polycythemia vera and primary thrombocythaemia
76. Outcome analysis of 34 pregnancies in women with essential thrombocythemia
77. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
78. Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: long-term results of a randomized clinical trial (abstract)
79. Long-term use of anagrelide in young patients with essential thrombocythemia (abstract)
80. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
81. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin
82. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia
83. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion
84. Management of polycythemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea
85. Pipobroman therapy of essential thrombocythemia
86. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients
87. Interferon alpha-2b in the long-term treatment of essential thrombocythemia
88. Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia
89. Primary thrombocythemia treated with busulphan
90. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia
91. The treatment of essential thrombocythaemia with radioactive phosphorus
92. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?
93. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - a 15 year review
94. Anagrelide: a new drug for treating thrombocytosis
95. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results
96. Treatment of essential thrombocythemia with anagrelide
97. Treatment of children with anagrelide for thrombocythemia
98. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia
99. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany
100. Acquired DNA mutations associated with in vivo hydroxyurea exposure
101. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature
102. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea
103. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications
104. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
105. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - a brief review of recent literature
106. Acute leukemia as a natural sequel to primary thrombocythemia
107. New drugs in essential thrombocythemia and polycythemia vera